The V-region binding antibody, RBGO1, bound to rRAGE with greater affinity than the other antibodies tested and was associated with rapid internalization, tracking to the lysosomal compartment and greater cytotoxicity in vitro, implying the importance of this aspect of ADC design for RAGE targeting and indeed, potentially when targeting other membrane receptors for cancer therapy. The gene discussed is AGER; the disease is cancer.